tbuckley/cabot-search huggingface dataset:
Meditation Intervention Reviews
Authors: Eric B. Loucks
Journal: JAMA Internal Medicine (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Making Medical Errors Into 'Medical Treasures'
Authors: David Blumenthal
Journal: JAMA (1994)

In his insightful and provocative article on medical error, Leape<sup>1</sup>raises a topic that has been distinctly unpopular among physicians. Concerning medical error and its prevention, the profession has, with rare exceptions, adopted an ostrichlike attitude. Mistakes have been treated as uncommon and atypical, requiring no remedy beyond the traditional incident reports and morbidity and mortality conferences. The manner in which physicians manage medical errors must and will change in the future. It will change because a large and growing collection of literature demonstrates that physicians' approaches to the management of medical error do not work well enough, and the various parties to which physicians are accountable—purchasers, payers, government, and the public—have discovered this fact. The only question now is whether new systems for preventing medical error will be designed with the full cooperation and participation of the profession or under less desirable circumstances. The See also p 1851.
Child of mother who drank excessively was not victim of crime, court rules
Authors: C. Dyer
Journal: BMJ (2014)

A 7 year old girl with fetal alcohol spectrum disorder is not entitled to a payout under the UK’s government funded criminal injuries compensation scheme, three Court of Appeal judges have ruled.

Lawyers for the girl, “CP,” argued that she was a victim of a violent crime when her mother’s grossly excessive drinking during pregnancy left her with learning, developmental, and behaviour problems.1

The judges ruled unanimously that “a mother who is pregnant and who drinks to excess despite knowledge of the potential harmful consequences to the child of doing so is not guilty of a criminal offence …
Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG–derived enzymes☆, ☆☆, ★, ★★
Authors: Y SUTAS, E SOPPI, H KORHONEN, E SYVAOJA, M SAXELIN, T ROKKA, E ISOLAURI
Journal: Journal of Allergy and Clinical Immunology (1996)
Is routine urine testing in outpatient clinics useful?
Authors: A. G. Morgan
Journal: BMJ (1988)

Des analyses d'urine systematiques pourraient etre tres utiles au depistage precoce d'affections encore asymptomatiques, si les medecins etaient plus attentifs a relever les resultats anormaux et a poursuivre les explorations jusqu'au diagnostic (reflexions a propos de tous les dossiers d'un hopital pendant 25 semaines)
TCT-119 European Multi-Center Experience with Direct Aortic Transcatheter Aortic Valve Implantation with a Self Expandable Valve
Authors: Giuseppe Bruschi, Hafid Amrane, Moninder Bhabra, Johan Bosmans, Marian Branny, Stephen Brecker, Hasan Bushnaq, Bernard Chevalier, Giuseppe Coletti, Haim Danenberg, Otto Dapunt, Federico De Marco, Peter den Heijer, Federica Ettori, Rudiger Lange, Bertrand Marcheix, Domenico Mazzitelli, Neil Moat, Thomas Modine, David Roy, Didier Tchetche, Uday Trivedi
Journal: Journal of the American College of Cardiology (2013)
The Role of Cations in Psychiatry.
Authors: Stanley Platman
Journal: Annals of Internal Medicine (1970)

Meeting Abstracts1 May 1970The Role of Cations in Psychiatry.Stanley Platman, M.D.Stanley Platman, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-72-5-807_6 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptLithium has now become an accepted therapy in the treatment and prevention of manic episodes. The empirical basis for its mechanism of action is considered to be related to alterations in the level of intracellular sodium.Based on a reduced intracellular potassium in depression, rubidium has been found to act as a potential modifier of affect and behavior.Lithium prevents the binding of sodium and potassium by strandin in neuronal membranes in vivo, whereas rubidium has an effect, in a sense, "opposite" to the effect of lithium in vitro on strandin constrained in an artificial "membrand." Forty ml (80 mEq)... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Stanley Platman, M.D.Affiliations: Brooklyn, N.Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1970Volume 72, Issue 5Page: 807-808KeywordsBehaviorCationsPotassiumSodium ePublished: 1 December 2008 Issue Published: 1 May 1970 PDF downloadLoading ...
Tolerance and Autoimmunity in Anti-GBM Disease
Authors: Alan D. Salama, Jeremy B. Levy
Journal: Journal of the American Society of Nephrology (2003)

Anti-glomerular basement membrane (GBM) or Goodpasture's disease is an uncommon cause of acute renal failure, with an incidence of only 0.5–1 cases/million per year, making it an unfamiliar clinical entity to many physicians. It has two recognized disease peaks in the third and seventh decades
Technetium-99m Red Blood Cell Venography of the Lower Limb in Symptomatic Pulmonary Embolization
Authors: ROBERT LISBONA, CHRISTOPHER RUSH, LUIGI LEPANTO
Journal: Clinical Nuclear Medicine (1987)

Tc-99m RBC venography of the legs was obtained in 42 patients with primary pulmonary symptomatology and a diagnosis of pulmonary embolization. In 31 of these 42 patients (74%), the nuclear venogram revealed the presence of deep vein thrombosis (DVT) and a source of embolization. Of the 31 patients with leg DVT documented by venography, 13 (42%) showed thrombosis confined to the calf. Clinical findings suggested that only 20 of the 31 patients (65%) with DVT could have harboured a source of embolization in the legs. Tc-99m RBC venography is a useful noninvasive test for the global and comprehensive assessment of patients with symptomatic pulmonary embolization.
Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution
Authors: Daisy F Lazarous, Matie Shou, Jonathan A Stiber, Darshana M Dadhania, Venugopal Thirumurti, Everett Hodge, Ellis F Unger
Journal: Cardiovascular Research (1997)

We have shown that basic fibroblast growth factor (bFGF/FGF-2) enhances myocardial collateral development in a canine model of progressive coronary occlusion when delivered via the left atrial or intracoronary routes; however, we have found intravenous bFGF ineffective in the same model. Data on the fate and efficacy of intravenous bFGF are limited. We hypothesized that first pass lung uptake might limit myocardial bFGF availability after intravenous injection. We postulated that delivery of bFGF through the distal port of a wedged Swan Ganz catheter might circumvent this problem by restricting exposure of bFGF to a limited number of pulmonary binding sites. This study evaluated differential regional uptake of 125I labeled bFGF following bolus intravenous, Swan Ganz, left atrial, intracoronary, and pericardial delivery.Mongrel dogs were used. Human recombinant bFGF, monoiodinated with 125I, was mixed with cold bFGF to a specific activity of 0.03 microCi/microgram. Approximately 100 micrograms/kg was injected per animal by the intravenous, left atrial, Swan Ganz, intracoronary, or pericardial route. Dogs were killed 15 min or 150 min later. The heart, lungs, liver, spleen, and kidneys were harvested and 125I activity was assessed. Immunohistochemical and pharmacokinetic studies were also performed.Serum half life of bFGF was comparable after intracoronary, intravenous and left atrial delivery (50 min); however, there were significant differences with regard to pharmacodynamics. After intracoronary administration, 3-5% of the total bFGF dose was recovered from the heart, with the peptide immunolocalized to the extracellular matrix and vascular endothelium. In contrast, only 1.3% of the injected bFGF was localized to the heart after left atrial administration and 0.5% was recovered after intravenous or Swan Ganz delivery. Pericardial administration resulted in substantial cardiac bFGF delivery; 19% was present at 150 min. Myocardial uptake was similar with Swan Ganz and intravenous delivery, suggesting that the administered dose did not saturate available pulmonary binding sites.These data predict efficacy of intracoronary, left atrial, and pericardial bFGF for myocardial angiogenesis, and a lack of efficacy after bolus intravenous and Swan Ganz administration.
264. Immune Gene-Therapy of Cancer Using Redirected Naïve or Effector Lymphocytes
Authors: Dinorah Friedmann-Morvinski, Tova Waks, Zelig Eshhar
Journal: Molecular Therapy (2006)

In order to expand the recognition spectrum of effector lymphocytes and redirect them in non-individual restricted manner to predefined targets, we have developed the 'T-body' approach for adoptive cancer immunotherapy, using chimeric receptor genes with antibody-type specificity. The modular structure of the chimeric receptor containing ecto-, scFv and spacer, transmembrane and cytoplasmic domains enabled its engineering to fit a desired task.
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study
Authors: Martin A. Champagne, Renaud Capdeville, Mark Krailo, Wenchun Qu, Bin Peng, Marianne Rosamilia, Martine Therrien, Ulrike Zoellner, Susan M. Blaney, Mark Bernstein
Journal: Blood (2004)
QUALITY OF LIFE AFTER MYOCARDIAL INFARCTION: FOUR-YEAR FOLLOW-UP OF THE GERMAN MYOCARDIAL INFARCTION FAMILY STUDY
Authors: Sabine J. Fenk, Ute Hubauer, Wibke Hengstenberg, Christine Meindl, Klaus Stark, Andrea Baessler, Marcus Fischer, Christian Hengstenberg
Journal: Journal of the American College of Cardiology (2013)
Carcinoma of the Thyroid Manifested as Hyperthyroidism Caused by Functional Bone Metastasis
Authors: KOJI IKEJIRI, MASATO FURUYAMA, TORU MURANAKA, HIDEAKI ANAI, SADANORI TAKEO, KIKUO SAKAI, MOTONORI SAKU, KOJI YOSHIDA
Journal: Clinical Nuclear Medicine (1997)

A rare case of hyperthyroidism in the presence of a functioning bone metastasis secondary to an occult thyroid cancer is reported. A 59-year-old woman's pelvic bone metastasis was much too extensive and hypervascular to permit resection. An I-131 scan showed striking activity in the pelvic metastasis, which reflected ectopic excessive production of thyroid hormone by a functioning metastatic thryoid carcinoma. After total thyroidectomy, the patient received I-131 ablation and transcutaneous intra-arterial embolization therapy but her metastasis progressively enlarged. Microscopically, concomitant follicular and papillary cancer was found in close proximity to the thyroid. The patient now has vertebral metastases, and her hyperthyroid state still requires methymazole to prevent thyrotoxicosis.
Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer
Authors: Luigi Marchionni, Renee F. Wilson, Antonio C. Wolff, Spyridon Marinopoulos, Giovanni Parmigiani, Eric B. Bass, Steven N. Goodman
Journal: Annals of Internal Medicine (2008)

Background: Three gene expression–based prognostic breast cancer tests have been licensed for use. Purpose: To summarize evidence on the validity and utility of 3 gene expression–based prognostic breast cancer tests: Oncotype DX (Genomic Health, Redwood City, California), MammaPrint (Agendia BV, Amsterdam, the Netherlands), and H/I (AvariaDX, Carlsbad, California). Data Sources: MEDLINE, EMBASE, and Cochrane databases (from 1990 through January 2007), Web sites of test manufacturers, and discussion with the manufacturers. Study Selection: Original data studies published in English that addressed prognostic accuracy and discrimination or treatment benefit prediction of any of the 3 tests in women with breast cancer. Data Extraction: Information was extracted about the clinical characteristics of the study population (particularly clinical and therapeutic homogeneity), tumor characteristics, and whether the marketed test or underlying signature was evaluated. Data Synthesis: The tests are based on distinct gene lists, using 2 different technologies. Overall, the body of evidence showed that this new generation of tests may improve prognostic and therapeutic prediction, but the tests are at different stages of development. Evidence shows that the tests offer clinically relevant, improved risk stratification over standard predictors. Oncotype DX has the strongest evidence, closely followed by MammaPrint and H/I (which is still maturing). Limitations: For all tests, the relationship of predicted to observed risk in different populations and their incremental contribution over conventional predictors, optimal implementation, and relevance to patients receiving current therapies need further study. Conclusion: Gene expression technologies show great promise to improve predictions of prognosis and treatment benefit for women with early-stage breast cancer. More information is needed on the extent of improvement in prediction, characteristics of women in whom the tests should be used, and how best to incorporate test results into decision making about breast cancer treatment.
INFANT DRESS.Read in the Section of Diseases of Children, at the Forty-second Annual Meeting of the American Medical Association, held at Washington, D. C., May, 1891.
Authors: FRANK S. PARSONS
Journal: JAMA (1891)

The average practitioner of medicine pays too little attention to the subject of infant dress. He goes about his daily duties, cares for and applies remedies to the sick infant, and, it may be, never gives a thought whether the child is properly clad, or if the material from which the clothes are made furnishes sufficient protection from the sudden atmospheric changes to which its delicate tissues are exposed. When he attends a confinement case, he seldom hints at any proper, hygienic method of arranging the baby's apparel, or dictates to the unscientific nurse what the infant shall wear. This leaves the subject to the mother, who, in the majority of cases, ignorantly binds the infant hand and foot, so that there is interference with the proper development of its muscles. Then, as the child struggles and cries for freedom, it is doomed to the conventional dose of peppermint or
Echocardiography for Assessing Cardiac Risk in Patients Having Noncardiac Surgery
Authors: Ethan A. Halm, Warren S. Browner, Julio F. Tubau, Ida M. Tateo, Dennis T. Mangano
Journal: Annals of Internal Medicine (1996)

Background: Cardiac complications after noncardiac surgery are a serious cause of illness and death. Echocardiography is being used before noncardiac surgery to assess risk for cardiac complications, but its role remains undefined. Objective: To examine the prognostic value and operating characteristics of transthoracic echocardiography for assessing cardiac risk before noncardiac surgery. Design: Prospective cohort study. Setting: University-affiliated Veterans Affairs medical center. Patients: 339 consecutive men who were known to have or were suspected of having coronary artery disease and were scheduled for major noncardiac surgery. Measurements: Information from detailed histories, physical examinations, and electrocardiographic and laboratory studies was routinely collected. Transthoracic echocardiography was done before surgery to assess ejection fraction, wall motion abnormalities (reported as the wall motion score [range, 5 to 25 points]), and left ventricular hypertrophy. Main Outcome Measures: Postoperative ischemic events (cardiac-related death, nonfatal myocardial infarction, and unstable angina), congestive heart failure, and ventricular tachycardia. Results: 10 patients (3%) had ischemic events; 26 (8%) had congestive heart failure; and 29 (8%) had ventricular tachycardia. No echocardiographic measurements were associated with ischemic events. In univariate analyses, an ejection fraction less than 40% was associated with all cardiac outcomes combined (odds ratio, 3.5 [95% CI, 1.8 to 6.7]), congestive heart failure (odds ratio, 3.0 [CI, 1.2 to 7.4]), and ventricular tachycardia (odds ratio, 2.6 [CI, 1.1 to 6.2]). In multivariable analyses that adjusted for known clinical risk factors, an ejection fraction less than 40% was a significant predictor of all outcomes combined (odds ratio, 2.5 [CI, 1.2 to 5.0]) but not congestive heart failure (odds ratio, 2.1 [CI, 0.7 to 6.0]) and ventricular ejection fraction (odds ratio, 1.8 [CI, 0.7 to 4.7]). Wall motion score was a univariate predictor of all cardiac outcomes (odds ratio for each 3-unit increase, 1.6 [CI, 1.3 to 2.1]) and ventricular tachycardia (odds ratio, 1.6 [CI, 1.2 to 2.2]) but was only a multivariable risk factor for all events (odds ratio, 1.3 [CI, 1.0 to 1.7]). An ejection fraction less than 40% had a sensitivity of 0.28 to 0.31 and a specificity of 0.87 to 0.89 for all categories of adverse outcomes. Likelihood ratios for ejection fraction had poor operating characteristics. Adding echocardiographic information to predictive models that contained known clinical risk factors did not alter sensitivity, specificity, or predictive values in clinically important ways. Conclusions: The data did not support the use of transthoracic echocardiography for the assessment of cardiac risk before noncardiac surgery. Echocardiographic measurements had limited prognostic value and suboptimal operating characteristics.
Ten-Year Prospective Follow-Up Study of the Naturalistic Course of Dysthymic Disorder and Double Depression
Authors: Daniel N. Klein, Stewart A. Shankman, Suzanne Rose
Journal: American Journal of Psychiatry (2006)

Objective: The purpose of this study was to describe the 10-year course and outcome of dysthymic disorder. Method: The authors conducted a naturalistic, prospective, longitudinal follow-up of 97 adults with early-onset dysthymic disorder and 45 adults with nonchronic major depressive disorder selected from consecutive admissions to several outpatient facilities. Follow-up data were obtained for 90% of the cohort. Assessments were conducted at baseline, 30, 60, 90, and 120 months. Measures included the Longitudinal Interval Follow-Up Evaluation and the Hamilton Depression Rating Scale. Results: The Kaplan-Meier estimated recovery rate from dysthymic disorder was 73.9%, with a median time to recovery of 52 months. Among patients who recovered, the estimated risk of relapse into another period of chronic depression was 71.4%. Chronic depressive relapses took a variety of forms and were not limited to dysthymia. Nonetheless, the distinction between chronic and nonchronic forms of depression was relatively stable over the follow-up period. Mixed-effects models indicated that patients with dysthymic disorder experienced a significantly slower rate of improvement in symptoms over time and exhibited significantly greater depression at the 10-year point, compared to patients with nonchronic major depression. Conclusions: Dysthymic disorder has a protracted course and is associated with a high risk of relapse. The nature of chronic depressive episodes varies over time within individuals, indicating that the various manifestations of chronic depression in DSM-IV do not represent distinct disorders. However, the distinction between chronic and nonchronic forms of depression is relatively stable and may provide a useful basis for subtyping in genetic and neurobiological research.
Angiographic determination of arterial patency after percutaneous catheterization in infants and small children.
Authors: R A Hurwitz, E A Franken, D A Girod, J A Smith, W L Smith
Journal: Circulation (1977)

Patency of the femoral artery of infants and children who previously had percutaneous arterial catheterization at a weight of less than 25 kg was studied angiographically. During the study period, 118 patients had repeat arterial catheterization. 48 from the opposite leg. Femoral artery occlusion was found in four patients, while 44 of the 48 studied from the opposite leg had complete patency. At the later study, all four with blockage were asymptomatic and possessed good pedal pulses, while two had decreased femoral pulsations. When events surrounding initial catheterization were retrospectively analyzed, three of four had decreased pedal pulsations beyond six hours. It is concluded that 3-8% of patients weighing less than 25 kg have arterial occlusion after catheterization. This complication may be entirely asymptomatic, but these patients will require continued observation for possible late vascular problems.
Hospital Infection and Visitors
Authors: A. M. Boyd
Journal: BMJ (1960)

Oral anticoagulants are commonly used drugs in patients with CKD and patients with ESKD to treat atrial fibrillation to reduce stroke and systemic embolism. Some of these drugs are used to treat or prevent deep venous thrombosis and pulmonary embolism in patients with CKD who undergo knee and hip replacement surgeries. Warfarin is the only anticoagulant that is approved for use by the Food and Drug Administration in individuals with mechanical heart valves. Each oral anticoagulant affects the coagulation profile in the laboratory uniquely. Warfarin and apixaban are the only anticoagulants that are Food and Drug Administration approved for use in patients with CKD and patients with ESKD. However, other oral anticoagulants are commonly used off label in this patient population. Given the acquired risk of bleeding from uremia, these drugs are known to cause increased bleeding events, hospitalization, and overall morbidity. Each anticoagulant has unique pharmacologic properties of which nephrologists need to be aware to optimally manage patients. In addition, nephrologists are increasingly asked to aid in the management of adverse bleeding events related to oral anticoagulant use in patients with CKD and patients with ESKD. This article summarizes the clinical pharmacology of these drugs and identifies knowledge gaps in the literature related to their use.
Cecal Kaposi's Sarcoma
Authors: Tamer Atassi, Elizabeth Montgomery
Journal: New England Journal of Medicine (2003)

A 35-year-old man with human immunodeficiency virus infection was admitted because of weight loss, fatigue, anorexia, and chronic, watery, nonbloody diarrhea. The workup for diarrhea revealed steatorrhea (110 g of fat per 24 hours). The patient had a history of chronic pancreatitis. A computed tomographic scan of the abdomen showed a cecal polypoid mass (arrow, Panel A). On colonoscopy, a 4-cm mass was seen at the cecum (Panel B). Examination of biopsy specimens of the mass showed proliferating spindle cells infiltrating the lamina propria, a finding consistent with the presence of Kaposi's sarcoma.